Sangui BioTech International Inc.
- WKN: 906757
- ISIN: US80105B1017
- Land: Germany
Nachricht vom 14.02.2020 | 11:10
Sangui BioTech International Inc.: Significant cost reductions in the first half - year; Significant reduction of operating loss
DGAP-News: Sangui BioTech International Inc.
/ Key word(s): Half Year Results
- Significant cost reductions in the first half - year
- Significant reduction of operating loss
Responsible for this development were measures for the integration of the licensee, SastoMed GmbH into the Mölnlycke Group. In particular, the restructuring of the sales and distribution channels in the Mölnlycke Group has taken some time. Mölnlycke believes that these measures will bear fruit with respect to revenue.
As operating expenses decreased USD 104,507 or 50% to USD 104,396 during the period, six-month operating loss decreased USD 61,204 to USD 92,431 from the prior year. The reason for this was cost savings in connection with the closure of the Witten site.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Sangui BioTech International Inc.: Practitione ...
Sangui BioTech International Inc.: Lower reven ...
Sangui BioTech International secures financial ...
Sangui BioTech International Inc.: Series of p ...
Sangui BioTech International Inc.: Revenues sl ...
MBH Corporation. Hohes Kurspotenzial
Die MBH Corporation plc hat in den vergangenen Berichtsperioden eine sehr hohe M&A-Aktivität aufgezeigt. Unter Anwendung der so genannten Agglomeration Methodology hat die Beteiligungsgesellschaft branchenübergreifend seit 2018 11 Beteiligungen erworben. Bei einem Pro-Forma-Umsatz der Beteiligungsgesellschaften von über 120 Mio. GBP und einem Pro-Forma-EBITDA in Höhe von über 11 Mio. GBP weist die MBH derzeit eine Marktkapitalisierung von umgerechnet gerade einmal 19,8 Mio. GBP auf. Ausgehend vom aktuellen Aktienkurs liegt zu unserem Kursziel in Höhe von 1,95 € ein hohes Kurspotenzial vor
Der AKTIONÄR News
29. März 18:21 Microsoft: Cloud wächst um 775 Prozent in einer Woche
29. März 17:24 Bayer: Das klingt richtig gut!
29. März 16:50 Novartis: Corona-Medikament – Zulassung per Eilverfahren?
Fourth Quarter Fiscal Year 2020 Results
06. April 2020
Original-Research: 3U HOLDING AG (von GSC Research GmbH): Kaufen
27. März 2020